한글목차

세계의 비출혈 시장 전망은 유망하며 소아 시장과 성인 시장에 기회가 있을 것으로 보입니다. 세계의 비출혈 시장은 2025-2031년 연평균 복합 성장률(CAGR) 5.0%를 보일 것으로 예측됩니다. 이 시장의 주요 촉진요인은 세계적인 소아 비출혈의 발생률 증가, 코 건강 관리에 대한 인식 증가, 국소 지혈제 사용 증가입니다.

• Lucintel의 예측에서 유형별로는 혈관수축제가 예측기간 중에 가장 높은 성장을 이룰 전망입니다.
• 용도별로는 소아가 높은 성장이 예상됩니다.
• 지역별로는 아시아태평양이 예측기간 동안 가장 높은 성장을 보일 전망입니다.

비출혈 시장의 새로운 동향

비출혈 시장은 침습성이 낮고 효과적이며 환자 중심의 치료 접근법을 향한 협력적 노력을 반영하여 몇 가지 주요 새로운 동향을 목격하고 있습니다. 이러한 동향은 기술적 진보, 진화하는 의료 행위, 환자의 쾌적성과 결과 관리에 중점을 두게 된 것이 배경에 있습니다.

• 저침습 치료 : 고도의 소작장치나 생체흡수성 비강 패킹 등 비출혈에 대한 저침습 치료를 개발 및 채용하는 경향이 강해지고 있습니다. 이러한 방법은 불편함을 줄이고 조직 손상을 최소화하며, 종종 회복 시간을 가속화하고 환자의 체감과 임상 효율을 향상시킵니다.
• 최첨단 지혈제 : 신규하고 효과적인 지혈제의 개발은 중요한 동향입니다. 여기에는 피브린 실란트나 콜라겐 스펀지와 같은 생체 흡수성 재료와 혁신적인 점비약이 포함됩니다. 이러한 약물은 기존의 포장보다 불쾌감이 적고 출혈을 억제하는 효과가 뛰어나 신속한 지혈로 이어집니다.
• 원격 의료 및 원격 모니터링 : 비출혈 관리를 위한 원격 의료 및 원격 모니터링 기술의 채택이 증가하고 있는 것은 새로운 추세입니다. 이를 통해 의료 서비스 제공업체가 직접 방문하지 않고도 시기 적절한 조언과 후속 조치를 제공할 수 있게 되며, 특히 원격지 환자의 경우 케어에 대한 액세스가 향상되고 환자 관리 개선이 촉진됩니다.
• 환자 중심 솔루션 : 환자의 편안함과 편의성을 강조하고 사용하기 쉬운 장비 및 제품 개발이 진행되고 있습니다. 코 팩의 삽입시나 제거시 통증의 경감, 외용약 용이성의 향상, 보다 부담이 적은 치료 옵션의 설계 등에 중점이 놓여, 전체적인 환자 만족도의 향상으로 이어지고 있습니다.
• 개인화된 치료 접근법 : 시장은 비출혈의 유형, 중증도 및 근본 원인에 기초하여 보다 개인화된 치료 계획으로 전환하고 있습니다. 이 추세는 진단 도구를 사용하여 출혈원을 정확하게 파악하고 치료 접근법을 조정하는 것을 포함하여 독특한 병리와 비출혈을 반복하는 환자의 치료 성적을 최적화합니다.

이러한 동향은 침습성이 낮고 보다 효과적인 치료법의 혁신을 촉진하고, 환자의 쾌적성을 향상시키고, 디지털 솔루션을 통해 치료에 대한 액세스를 확대함으로써 비출혈 시장을 크게 재구성하고 있습니다. 시장은 다양한 환자 집단의 복잡한 요구를 충족하고 비출혈 관리 전체를 개선하기 위해 진화하고 있습니다.

비출혈 시장의 최근 동향

비출혈 시장은 비출혈을 관리하는 효율적이고 침습성이 낮은 방법에 대한 요구가 증가하고 그 근본 원인에 대한 이해가 높아짐에 따라 최근의 동향이 주목 받고 있습니다. 이러한 진보는 환자의 예후를 개선하고 이용 가능한 치료 옵션의 폭을 넓히고 있습니다.

• 새로운 비강 탐폰에이드의 도입 : 중요한 개발은 혁신적인 비강 탐폰에이드의 출시입니다. 이들은 팽창식 풍선에 고도의 겔화 소재와 비대칭 디자인을 결합하여 삽입을 간편화하고 효과적인 지혈을 확보하고 제거시 통증을 줄임으로써 환자의 쾌적성을 대폭 향상시키고 있습니다.
• 지혈제의 진보 : 고급 지혈제의 개발이 계속되고 있습니다. 여기에는 트라넥삼산과 같은 보다 효과적인 외용제와 콜라겐 스펀지 및 피브린 실란트와 같은 생체 흡수성 물질이 포함됩니다. 이 약들은 지혈 효과를 향상시키고 종종 침습적인 치료의 필요성을 줄입니다.
• 저침습 수술에 대한 관심 증가 : 이 시장에서는 나비입천장동맥의 내시경 과정과 전기 소작법 개선과 같은 저침습 수술 절차로의 강한 전환을 볼 수 있습니다. 이러한 절차는 전통적인 수술 중재와 비교하여 환자의 회복 시간을 가속화하고 불쾌감을 줄입니다.
• 장비의 기술 통합 : 개발에는 3D 프린팅과 같은 첨단 기술의 통합과 비출혈 풍선 카테터의 AI 지원 네비게이션 시스템의 가능성 등이 포함됩니다. 이러한 기술 혁신은 출혈 부위를 보다 정확하게 시각화하고 치료의 효능과 효율성을 향상시키는 것을 목표로 합니다.
• 가정 관리 솔루션의 중요성 : 사용자 친화적인 가정 비출혈 관리 시스템의 개발이 새로운 동향이 되었습니다. 이러한 솔루션은 환자의 편안함과 비용 효율성을 우선시하고 집중에서 경도에서 중등도의 비출혈을 효과적으로 관리할 수 있게 함으로써 의료시설 부담을 줄여줍니다.

이러한 개발은 환자에게 친화적이고 효율적이며 기술적으로 진행되는 치료법을 제공함으로써 비출혈 시장에 큰 영향을 미칩니다. 끊임없는 기술 혁신은 다양한 중증도에서 비출혈 관리의 효능을 강화하고 환자 관리와 결과를 개선합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계의 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 비출혈 시장 : 유형별

• 개요
• 매력 분석 : 유형별
• 혈관수축약 : 동향과 예측(2019-2031년)
• 마취약 : 동향과 예측(2019-2031년)
• 항생물질 연고 : 동향과 예측(2019-2031년)
• 소작제 : 동향과 예측(2019-2031년)

제5장 세계의 비출혈 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 소아 : 동향과 예측(2019-2031년)
• 성인 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 비출혈 시장 : 지역별

제7장 북미의 비출혈 시장

• 개요
• 북미의 비출혈 시장 : 유형별
• 북미의 비출혈 시장 : 용도별
• 미국의 비출혈 시장
• 멕시코 비출혈 시장
• 캐나다의 비출혈 시장

제8장 유럽의 비출혈 시장

• 개요
• 유럽의 비출혈 시장 : 유형별
• 유럽의 비출혈 시장 : 용도별
• 독일의 비출혈 시장
• 프랑스의 비출혈 시장
• 스페인 비출혈 시장
• 이탈리아의 비출혈 시장
• 영국의 비출혈 시장

제9장 아시아태평양의 비출혈 시장

• 개요
• 아시아태평양의 비출혈 시장 : 유형별
• 아시아태평양의 비출혈 시장 : 용도별
• 일본의 비출혈 시장
• 인도의 비출혈 시장
• 중국의 비출혈 시장
• 한국의 비출혈 시장
• 인도네시아의 비출혈 시장

제10장 기타 지역(ROW)의 비출혈 시장

• 개요
• ROW의 비출혈 시장 : 유형별
• ROW의 비출혈 시장 : 용도별
• 중동의 비출혈 시장
• 남미의 비출혈 시장
• 아프리카의 비출혈 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업간 경쟁 관계
  • 바이어의 협상력
  • 공급자의 협상력
  • 대체품의 위협
  • 신규 참가업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 유형별
  • 성장 기회 : 용도별
• 세계 비출혈 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증 및 라이선싱
  • 기업 인수합병(M&A), 계약, 제휴, 합작 사업

제13장 밸류체인의 주요 기업 프로파일

• 경쟁 분석
• AbbVie
• Allergan
• Amgen
• AstraZeneca
• Bayer
• Boehringer Ingelheim International
• Bristol-Myers Squibb Pharma Company
• Ciron Drugs
• Dr. Reddy's Laboratories
• Eli Lilly and Company

제14장 부록

• 그림 일람
• 표 일람
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel 소개
• 문의

영문목차

The future of the global epistaxis market looks promising with opportunities in the pediatric and adult markets. The global epistaxis market is expected to grow with a CAGR of 5.0% from 2025 to 2031. The major drivers for this market are the increasing pediatric epistaxis incidence worldwide, the rising awareness about nasal health management, and the growing use of topical hemostatic agents.

• Lucintel forecasts that, within the type category, vasoconstrictor is expected to witness the highest growth over the forecast period.
• Within the application category, pediatric is expected to witness higher growth.
• In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Epistaxis Market

The epistaxis market is witnessing several key emerging trends, reflecting a concerted effort towards less invasive, more effective, and patient-centric treatment approaches. These trends are driven by technological advancements, evolving medical practices, and a growing emphasis on managing patient comfort and outcomes.

• Minimally Invasive Treatments: There's a strong trend towards developing and adopting minimally invasive treatments for epistaxis, such as advanced cautery devices and bio-absorbable nasal packing. These methods reduce discomfort, minimize tissue damage, and often lead to faster recovery times, improving the patient experience and clinical efficiency.
• Advanced Hemostatic Agents: The development of novel and more effective hemostatic agents is a significant trend. This includes bio-absorbable materials like fibrin sealants and collagen sponges, as well as innovative nasal sprays. These agents offer superior efficacy in controlling bleeding with less discomfort than traditional packing, leading to quicker hemostasis.
• Telehealth and Remote Monitoring: The increasing adoption of telehealth and remote monitoring technologies for epistaxis management is an emerging trend. This allows for better access to care, especially for patients in remote areas, and facilitates improved patient management, enabling healthcare providers to offer timely advice and follow-up without in-person visits.
• Patient-Centric Solutions: A growing emphasis on patient comfort and convenience is driving the development of user-friendly devices and products. Innovations focus on reducing pain during insertion and removal of nasal packing, improving ease of application for topical agents, and designing less intrusive treatment options, enhancing overall patient satisfaction.
• Personalized Treatment Approaches: The market is moving towards more personalized treatment plans based on the type, severity, and underlying cause of epistaxis. This trend involves using diagnostic tools to accurately identify the bleeding source and then tailoring the treatment approach, optimizing outcomes for patients with unique medical conditions or recurrent nosebleeds.

These trends are significantly reshaping the epistaxis market by fostering innovation in less invasive and more effective treatments, enhancing patient comfort, and broadening access to care through digital solutions. The market is evolving to meet the complex demands of diverse patient populations and improving overall epistaxis management.

Recent Developments in the Epistaxis Market

The epistaxis market has seen notable recent developments, driven by the increasing need for efficient and less invasive methods to manage nosebleeds, coupled with a rising understanding of their underlying causes. These advancements are improving patient outcomes and expanding the range of available treatment options.

• Introduction of Novel Nasal Tamponades: A significant development is the launch of innovative nasal tamponade devices, such. These combine inflatable balloons with advanced gelling fabrics or asymmetric designs, simplifying insertion, ensuring effective hemostasis, and significantly enhancing patient comfort by reducing pain upon removal.
• Advancements in Hemostatic Agents: There's been continuous development in advanced hemostatic agents. This includes more effective topical applications like tranexamic acid, and bio-absorbable materials like collagen sponges or fibrin sealants. These agents offer improved efficacy in stopping bleeding, often reducing the need for more invasive procedures.
• Increased Focus on Minimally Invasive Procedures: The market is seeing a strong shift towards minimally invasive surgical techniques, such as endoscopic litigation of the sphenopalatine artery and improved electrocautery methods. These procedures result in faster recovery times and less discomfort for patients compared to traditional surgical interventions.
• Technological Integration in Devices: Developments include the integration of advanced technologies like 3D printing and potentially AI-assisted navigation systems for epistaxis balloon catheters. These innovations aim to provide better visualization of bleeding sites and more precise placement, enhancing the effectiveness and efficiency of procedures.
• Emphasis on Home-Based Management Solutions: There's an emerging trend towards developing user-friendly, home-based epistaxis management systems. These solutions prioritize patient comfort and cost-efficiency, allowing individuals to manage mild to moderate nosebleeds effectively at home, reducing the burden on healthcare facilities.

These developments are significantly impacting the epistaxis market by offering more patient-friendly, efficient, and technologically advanced treatment options. The continuous innovation is enhancing the effectiveness of epistaxis management across various severities, leading to improved patient care and outcomes.

Strategic Growth Opportunities in the Epistaxis Market

The epistaxis market presents substantial strategic growth opportunities across various key applications, driven by the increasing prevalence of nosebleeds and the demand for effective, patient-friendly interventions. Capitalizing on these requires a focused approach on product development and market penetration in specific medical settings.

• Hospital & Clinic Settings (Emergency Management): This remains a primary growth area, as severe epistaxis cases often require immediate medical attention. Opportunities lie in developing advanced nasal packing devices, cautery tools, and surgical instruments that offer rapid hemostasis and are suitable for use in emergency departments and ENT clinics, enhancing efficiency in critical situations.
• Homecare & Self-Management Solutions: With an aging population and increasing demand for convenient care, home-based epistaxis management offers a significant opportunity. This includes user-friendly nasal sprays, topical hemostatic gels, and simple nasal packing kits that patients can safely use at home for minor nosebleeds, reducing hospital visits and improving comfort.
• Pediatric Applications (Gentle Solutions): Epistaxis is common in children, creating a niche for pediatric-specific solutions. Growth opportunities involve developing smaller, less invasive, and more comfortable devices and topical agents suitable for children, prioritizing gentle treatment and minimizing distress during the procedure.
• Surgical Interventions (Specialized Procedures): For recurrent or severe posterior epistaxis, surgical interventions like sphenopalatine artery ligation remain crucial. Strategic growth involves refining surgical instruments and techniques, potentially integrating endoscopic and minimally invasive approaches, to improve precision, reduce recovery time, and enhance long-term outcomes.
• Pharmacy and Retail Sales (OTC Products): Expanding the availability of over-the-counter (OTC) products for minor nosebleeds in pharmacies and retail channels presents a considerable opportunity. This includes saline nasal sprays, topical vasoconstrictors, and simple nasal clips, catering to immediate consumer needs and promoting self-care for mild cases.

These opportunities are significantly impacting the epistaxis market by driving specialized product development across different care settings. The focus on enhancing immediate care in hospitals, empowering home management, and tailoring solutions for specific patient demographics is ensuring sustained demand and market expansion.

Epistaxis Market Driver and Challenges

The epistaxis market is shaped by a complex interplay of major drivers that propel its growth and key challenges that can hinder its expansion. These factors, encompassing demographic shifts, technological innovations, and healthcare infrastructure, collectively determine the market's trajectory.

The factors responsible for driving the epistaxis market include:

1. Rising Prevalence of Epistaxis: The increasing incidence of nosebleeds globally, often linked to underlying conditions like hypertension, cardiovascular diseases, and nasal trauma, is a primary driver. This growing patient volume necessitates more effective and accessible treatment options, fueling market expansion.

2. Aging Global Population: An aging demographic is a significant driver, as older individuals are more prone to epistaxis due to increased vascular fragility and the use of anticoagulant medications. This demographic shift naturally increases the demand for epistaxis management products and services, particularly in developed regions.

3. Technological Advancements in Treatments: Continuous innovations in treatment modalities, including the development of advanced hemostatic agents (e.g., bio-absorbable materials), improved cautery devices, and minimally invasive surgical techniques, are enhancing treatment efficacy and patient comfort, driving market growth.

4. Increased Awareness and Diagnosis: Growing awareness among both healthcare professionals and the general public about effective epistaxis management techniques and the importance of timely intervention is driving demand. Better diagnostic tools also contribute to more accurate identification and treatment of bleeding sources.

5. Rising Healthcare Expenditure: Increasing healthcare expenditure globally, particularly in developing economies, leads to improved access to medical facilities and advanced treatment options. This financial investment supports the adoption of newer epistaxis management products and technologies, contributing to market expansion.

Challenges in the epistaxis market are:

1. Variability in Treatment Efficacy: The effectiveness of epistaxis treatments can vary significantly depending on the underlying cause, severity, and location of the bleed. This variability can complicate treatment protocols and outcomes, posing a challenge for developing universally effective solutions.

2. High Cost of Advanced Devices: While advanced hemostatic agents and minimally invasive devices offer superior benefits, their often-higher cost compared to traditional methods can be a barrier to adoption, especially in budget-constrained healthcare systems or developing regions.

3. Lack of Awareness in Rural Areas: In underserved or rural areas, there can be a significant lack of awareness regarding advanced epistaxis treatment options and limited access to specialized ENT care. This can impede timely and effective treatment, hindering market penetration in these regions.

The overall impact of these drivers and challenges on the epistaxis market is a continuous push towards innovative, patient-friendly solutions driven by an aging population and increasing disease prevalence. However, addressing the variability in treatment outcomes, cost barriers, and improving accessibility to advanced care remain crucial for sustained market growth and equitable patient care.

List of Epistaxis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies epistaxis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the epistaxis companies profiled in this report include-

• AbbVie
• Allergan
• Amgen
• AstraZeneca
• Bayer
• Boehringer Ingelheim International
• Bristol-Myers Squibb Pharma Company
• Ciron Drugs
• Dr. Reddy's Laboratories
• Eli Lilly and Company

Epistaxis Market by Segment

The study includes a forecast for the global epistaxis market by type, application, and region.

Epistaxis Market by Type [Value from 2019 to 2031]:

• Vasoconstrictors
• Anesthetics
• Antibiotic Ointments
• Cauterizing Agents

Epistaxis Market by Application [Value from 2019 to 2031]:

• Pediatric
• Adult

Epistaxis Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Epistaxis Market

The epistaxis market is experiencing significant growth, driven by an aging global population, rising prevalence of hypertension and other predisposing conditions, and continuous advancements in treatment modalities. Recent developments are focused on developing minimally invasive solutions, enhancing patient comfort, and improving the efficacy of hemostatic agents and devices to manage various types of nosebleeds more effectively.

• United States: The U.S. epistaxis market is marked by high healthcare expenditure and advanced infrastructure, leading to significant R&D in novel hemostatic agents and minimally invasive procedures. Recent FDA approvals for innovative nasal tampons and the launch of new hemostatic dressings by companies like Medline and Smith & Nephew signify a strong drive towards effective, patient-friendly solutions.
• China: China epistaxis market is expanding rapidly due to increasing healthcare investments and a growing awareness of nasal health. While no specific country-level product launches were immediately available, the overall Asia Pacific region is expected to grow, driven by urbanization and healthcare infrastructure development, indicating a rising demand for effective epistaxis management.
• Germany: Germany epistaxis market focuses on quality and efficacy in treatment. While specific recent product launches weren't highlighted, the European market as a whole is characterized by a high adoption of advanced treatment options. The emphasis is on safe and effective solutions for managing nosebleeds, aligning with robust healthcare systems and patient safety standards.
• India: India epistaxis market is witnessing growth driven by increasing health awareness and improvements in medical facilities. Studies in India show a high prevalence of epistaxis, particularly due to trauma and hypertension. The focus is on effective emergency room treatments, including anterior nasal packing, and an increasing understanding of risk factors, leading to better management strategies.
• Japan: While specific recent developments for the epistaxis market in Japan were not readily available, the broader healthcare landscape in Japan emphasizes high-quality medical devices and precision. This suggests a market that would likely adopt advanced, minimally invasive epistaxis treatments and innovative hemostatic products as they become available.

Features of the Global Epistaxis Market

• Market Size Estimates: Epistaxis market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Epistaxis market size by type, applications, and region in terms of value ($B).
• Regional Analysis: Epistaxis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the epistaxis market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the epistaxis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the epistaxis market by type (vasoconstrictors, anesthetics, antibiotic ointments, and cauterizing agents), application (pediatric and adult), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Epistaxis Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 Vasoconstrictors: Trends and Forecast (2019-2031)
• 4.4 Anesthetics: Trends and Forecast (2019-2031)
• 4.5 Antibiotic Ointments: Trends and Forecast (2019-2031)
• 4.6 Cauterizing Agents: Trends and Forecast (2019-2031)

5. Global Epistaxis Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Pediatric: Trends and Forecast (2019-2031)
• 5.4 Adult: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Epistaxis Market by Region

7. North American Epistaxis Market

• 7.1 Overview
• 7.2 North American Epistaxis Market by Type
• 7.3 North American Epistaxis Market by Application
• 7.4 United States Epistaxis Market
• 7.5 Mexican Epistaxis Market
• 7.6 Canadian Epistaxis Market

8. European Epistaxis Market

• 8.1 Overview
• 8.2 European Epistaxis Market by Type
• 8.3 European Epistaxis Market by Application
• 8.4 German Epistaxis Market
• 8.5 French Epistaxis Market
• 8.6 Spanish Epistaxis Market
• 8.7 Italian Epistaxis Market
• 8.8 United Kingdom Epistaxis Market

9. APAC Epistaxis Market

• 9.1 Overview
• 9.2 APAC Epistaxis Market by Type
• 9.3 APAC Epistaxis Market by Application
• 9.4 Japanese Epistaxis Market
• 9.5 Indian Epistaxis Market
• 9.6 Chinese Epistaxis Market
• 9.7 South Korean Epistaxis Market
• 9.8 Indonesian Epistaxis Market

10. ROW Epistaxis Market

• 10.1 Overview
• 10.2 ROW Epistaxis Market by Type
• 10.3 ROW Epistaxis Market by Application
• 10.4 Middle Eastern Epistaxis Market
• 10.5 South American Epistaxis Market
• 10.6 African Epistaxis Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Epistaxis Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 AbbVie
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Allergan
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 Amgen
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 AstraZeneca
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Bayer
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Boehringer Ingelheim International
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Bristol-Myers Squibb Pharma Company
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Ciron Drugs
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Dr. Reddy's Laboratories
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Eli Lilly and Company
  • Company Overview
  • Epistaxis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us